News

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor.

The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes.

The name of the investor was not disclosed, but Adial said a “health care-focused institutional investor” has entered into a warrant inducement agreement to purchase up to 2.3 million shares in the company at a reduced price of 74 cents per share. The deal was expected to close this week.

In April, Adial was granted a U.S. patent for a new treatment of disorders and diseases related to alcohol and opioid abuse for genetically identified patients. The company is using an investigational drug called AD04 for patients with serotonin-related gene variations.

“By identifying genetic markers associated with AD04 response, we are pioneering a precision medicine approach for [alcohol use disorder] that has the potential to enhance treatment efficacy and improve patient outcomes,” CEO Cary Claiborne said in a statement. “We remain committed to advancing AD04 through clinical development and regulatory pathways to address the urgent need for effective, personalized addiction treatments.”

Adial, which was formerly based in Charlottesville, raised $7.32 million in an IPO in 2018.

Read more here.

Recent News

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …